bpc 157 works orally BPC-157 ORAL BPC 157 is the injury
Description
In 2023, the FDA designated BPC-157 as a Category 2 bulk drug substance, meaning it cannot be compounded by commercial pharmaceutical companies, and there is insufficient evidence regarding potential harm to humans
BPC-157 dosage: 250 to 300 mcg subcutaneously twice daily near the affected disc level
Pharmaceuticals, 16 (7), Article 967
& Matter, K
Add an appropriate volume of BAC water directly to the vial, then gently swirl do not shake until the powder is fully dissolved
Only medical experts who are truly qualified to perform anti-aging treatments should administer them
